WO2026139739 - DUAL BINDING COMPOSITIONS TARGETING VEGFA AND PD-1
National phase entry is expected:
Publication Number
WO/2026/139739
Publication Date
02.07.2026
International Application No.
PCT/IB2025/060506
International Filing Date
15.10.2025
Title **
[English]
DUAL BINDING COMPOSITIONS TARGETING VEGFA AND PD-1
[French]
COMPOSITIONS À DOUBLE LIAISON CIBLANT VEGFA ET PD-1
Applicants **
BRIGHT PEAK THERAPEUTICS AG
Inventors
PATTABIRAMAN, Vijaya Raghavan
KREFT, Bertolt
GOEPFERT, Arnaud
MARTIN, Kea
RESCHKE, Nina
BORNERT, Olivier
Priority Data
63/739,333
27.12.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 6710 | |
| EPO | Filing, Examination, Granting | 136927 | |
| Japan | Filing, Examination, Granting | 5082 | |
| South Korea | Filing, Examination, Granting | 9458 | |
| USA | Filing, Examination, Granting | 31290 |
Total:
189,467
Contact Us
Abstract[English]
The present disclosure relates to dual binding compositions specific for PD-1 and VEGFA.[French]
La présente divulgation concerne des compositions à double liaison spécifiques de PD-1 et VEGFA.